Higher hydroxyurea adherence among young adults with sickle cell disease compared to children and adolescents

References

• National Heart, Lung and Blood Institute. What is sickle cell anemia? 2012 [cited 15 February 2021]. Available from: http://www.nhlbi.nih.gov/health/health-topics/topics/sca/.
   Google Scholar
• Hassell KL. Population estimates of sickle cell disease in the U.S. Am J Prev Med. 2010;38(4 Suppl):S512–S521.
   PubMed Web of Science ®Google Scholar
• Brousseau DC, Panepinto JA, Nimmer M, et al. The number of people with sickle-cell disease in the United States: national and state estimates. Am J Hematol. 2010; 85(1):77–78.
   PubMed Web of Science ®Google Scholar
• Kato GJ, Piel FB, Reid CD, et al. Sickle cell disease. Nat Rev Dis Primers. 2018;4:18010.
   PubMed Web of Science ®Google Scholar
• Palermo TM, Schwartz L, Drotar D, et al. Parental report of health-related quality of life in children with sickle cell disease. J Behav Med. 2002; 25(3):269–283.
   PubMed Web of Science ®Google Scholar
• Ameringer S, Elswick RK, Jr, Smith W. Fatigue in adolescents and young adults with sickle cell disease: biological and behavioral correlates and health-related quality of life. J Pediatr Oncol Nurs. 2014;31(1):6–17.
   PubMed Web of Science ®Google Scholar
• Dampier C, LeBeau P, Rhee S, et al. Health-related quality of life in adults with sickle cell disease (SCD): a report from the comprehensive sickle cell centers clinical trial consortium. Am J Hematol. 2011;86(2):203–205.
   PubMed Web of Science ®Google Scholar
• Jackson JL, Lemanek KL, Clough-Paabo E, et al. Predictors of health-related quality of life over time among adolescents and young adults with sickle cell disease. J Clin Psychol Med Settings. 2014;21(4) :313–319.
   PubMed Web of Science ®Google Scholar
• Panepinto JA, Bonner M. Health-related quality of life in sickle cell disease: past, present, and future. Pediatr Blood Cancer. 2012;59(2):377–385.
   PubMed Web of Science ®Google Scholar
• Panepinto JA, O'Mahar KM, DeBaun MR, et al. Health-related quality of life in children with sickle cell disease: child and parent perception. Br J Haematol. 2005;130(3):437–444.
   PubMed Web of Science ®Google Scholar
• Shankar SM, Arbogast PG, Mitchel E, et al. Medical care utilization and mortality in sickle cell disease: a population-based study. Am J Hematol. 2005;80(4):262–270.
   PubMed Web of Science ®Google Scholar
• Akenroye AT, Thurm CW, Neuman MI, et al. Prevelance and predictors of return visits to pediatric emergency departments. J Hosp Med. 2014;9(12):779–787.
   PubMed Web of Science ®Google Scholar
• Lubeck D, Agodoa I, Bhakta N, et al. Estimated life expectancy and income of patients with sickle cell disease compared with those without sickle cell disease. JAMA Netw Open. 2019;2(11):e1915374.
   PubMed Web of Science ®Google Scholar
• Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet. 2011;377(9778):1663–1672.
   PubMed Web of Science ®Google Scholar
• Strouse JJ, Lanzkron S, Beach MC, et al. Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children. Pediatrics. 2008;122(6):1332–1342.
   PubMed Web of Science ®Google Scholar
• Segal JB, Strouse JJ, Beach MC, et al. Hydroxyurea for the treatment of sickle cell disease. Evid Rep Technol Assess (Full Rep). 2008;(165):1–95.
   PubMedGoogle Scholar
• Thornburg CD, Files BA, Luo Z, et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood. 2012;120(22):4304–4310; quiz 4448.
   PubMed Web of Science ®Google Scholar
• Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. N Engl J Med. 1995;332(20):1317–1322.
   PubMed Web of Science ®Google Scholar
• Thornburg CD, Calatroni A, Panepinto JA. Differences in health-related quality of life in children with sickle cell disease receiving hydroxyurea. J Pediatr Hematol Oncol. 2011;33(4):251–254.
   PubMed Web of Science ®Google Scholar
• Ballas SK, Barton FB, Waclawiw MA, et al. Hydroxyurea and sickle cell anemia: effect on quality of life. Health Qual Life Outcomes. 2006;4:59.
   PubMed Web of Science ®Google Scholar
• Badawy SM, Thompson AA, Lai J-S, et al. Health-related quality of life and adherence to hydroxyurea in adolescents and young adults with sickle cell disease. Pediatr Blood Cancer. 2017;64(6):e26369.
   Web of Science ®Google Scholar
• Badawy SM, Thompson A, Holl J, et al. Healthcare utilization and hydroxyurea adherence in youth with sickle cell disease. Pediatr Hematol Oncol. 2018; 35(5–6):297–308.
   PubMed Web of Science ®Google Scholar
• Badawy SM, Barrera L, Cai S, et al. Association between participants’ characteristics, patient-reported outcomes, and clinical outcomes in youth with sickle cell Disease. Biomed Res Int. 2018;2018:8296139.
   PubMed Web of Science ®Google Scholar
• Badawy SM, Thompson AA, Lai JS, et al. Adherence to hydroxyurea, health-related quality of life domains, and patients' perceptions of sickle cell disease and hydroxyurea: a cross-sectional study in adolescents and young adults. Health Qual Life Outcomes. 2017;15(1):136.
   PubMedGoogle Scholar
• Badawy SM, Payne AB. Association between clinical outcomes and metformin use in adults with sickle cell disease and diabetes mellitus. Blood Adv. 2019;3(21):3297–3306.
   PubMed Web of Science ®Google Scholar
• Ali MA, Ahmad A, Chaudry H, et al. Efficacy and safety of recently approved drugs for sickle cell disease: a review of clinical trials. Exp Hematol. 2020;92:11–18.e1.
   PubMed Web of Science ®Google Scholar
• Fingar KR, Owens PL, Reid LD, et al. Healthcare cost and utilization project (HCUP) statistical briefs. Agency for Healthcare Research and Quality; Rockville, MD: 2019. Characteristics of inpatient hospital stays involving sickle cell disease, 2000–2016: Statistical Brief #251.
   Google Scholar
• Wang WC, Oyeku SO, Luo Z, et al. Hydroxyurea is associated with lower costs of care of young children with sickle cell anemia. Pediatrics. 2013;132(4):677–683.
   PubMed Web of Science ®Google Scholar
• Walsh KE, Cutrona SL, Kavanagh PL, et al. Medication adherence among pediatric patients with sickle cell disease: a systematic review. Pediatrics. 2014;134(6):1175–1183.
   PubMed Web of Science ®Google Scholar
• Badawy SM, Thompson AA, Liem RI. Technology access and smartphone app preferences for medication adherence in adolescents and young adults with sickle cell Disease. Pediatr Blood Cancer. 2016;63(5):848–852.
   PubMed Web of Science ®Google Scholar
• Thornburg CD, Calatroni A, Telen M, et al. Adherence to hydroxyurea therapy in children with sickle cell anemia. J Pediatr. 2010;156(3):415–419.
   PubMed Web of Science ®Google Scholar
• Loiselle K, Lee JL, Szulczewski L, et al. Systematic and meta-analytic review: medication adherence among pediatric patients with sickle cell disease. J Pediatr Psychol. 2016;41(4):406–418.
   PubMed Web of Science ®Google Scholar
• Modi AC, Crosby LE, Guilfoyle SM, et al. Barriers to treatment adherence for pediatric patients with sickle cell disease and their families. Children’s Health Care. 2009;38(2):107–122.
   Web of Science ®Google Scholar
• Brandow AM, Panepinto JA. Monitoring toxicity, impact, and adherence of hydroxyurea in children with sickle cell disease. Am J Hematol. 2011;86(9):804–806.
   PubMed Web of Science ®Google Scholar
• Badawy SM, Thompson AA, Penedo FJ, et al. Barriers to hydroxyurea adherence and health-related quality of life in adolescents and young adults with sickle cell disease. Eur J Haematol. 2017;98(6):608–614.
   PubMed Web of Science ®Google Scholar
• Nietert PJ, Abboud MR, Zoller JS, et al. Costs, charges, and reimbursements for persons with sickle cell disease. J Pediatr Hematol Oncol. 1999;21(5):389–396.
   PubMed Web of Science ®Google Scholar
• Raphael JL, Mei M, Mueller BU, et al. High resource hospitalizations among children with vaso-occlusive crises in sickle cell disease. Pediatr Blood Cancer. 2012;58(4):584–590.
   PubMed Web of Science ®Google Scholar
• Creary S, Modi A, Stanek J, et al. Allocation of treatment responsibility and adherence to hydroxyurea among adolescents with sickle cell disease. J Pediatr Psychol. 2019;44(10):1196–1204.
   PubMed Web of Science ®Google Scholar
• Berkowitz S, Traore C, Singer D, et al. Evaluating area-based socioeconomic status indicators for monitoring disparities within healthcare systems: results from a primary care network. Health Serv Res. 2015;50(2):398–417.
   PubMed Web of Science ®Google Scholar
• U.S. Census Bureau. Illinois median household income, 2018, 2015-2019, American Community Survey 5-year estimates. Available from: https://www.census.gov/quickfacts/IL.
   Google Scholar
• Ware RE. How I use hydroxyurea to treat young patients with sickle cell anemia. Blood. 2010;115(26):5300–5311.
   PubMed Web of Science ®Google Scholar
• Heeney MM, Ware RE. Hydroxyurea for children with sickle cell disease. Hematol Oncol Clin North Am. 2010;24(1):199–214.
   PubMed Web of Science ®Google Scholar
• Anders DG, Tang F, Ledneva T, et al. Hydroxyurea use in young children with sickle cell anemia in New York state. Am J Prev Med. 2016;51(1 Suppl 1):S31–S38.
   PubMed Web of Science ®Google Scholar
• Estepp JH, Smeltzer MP, Kang G, et al. A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy. Am J Hematol. 2017;92(12):1333–1339.
   PubMed Web of Science ®Google Scholar
• Phillips K, Healy L, Smith L, et al. Hydroxyurea therapy in UK children with sickle cell anaemia: a single-Centre experience. Pediatr Blood Cancer. 2018;65(2):e26833.
   Web of Science ®Google Scholar
• Candrilli SD, O'Brien SH, Ware RE, et al. Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease. Am J Hematol. 2011;86(3):273–277.
   PubMed Web of Science ®Google Scholar
• Houston-Yu P, Rana SR, Beyer B, et al. Frequent and prolonged hospitalizations: a risk factor for early mortality in sickle cell disease patients. Am J Hematol. 2003;72(3):201–203.
   PubMed Web of Science ®Google Scholar
• Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312(10):1033–1048.
   PubMed Web of Science ®Google Scholar
• Nevitt SJ, Jones AP, Howard J. Hydroxyurea (hydroxycarbamide) for sickle cell disease. Cochrane Database Syst Rev. 2017;4:CD002202.
   PubMedGoogle Scholar
• Crego N, Douglas C, Bonnabeau E, et al. Sickle-cell disease co-management, health care utilization, and hydroxyurea use. J Am Board Fam Med. 2020; 33(1):91–105.
   PubMed Web of Science ®Google Scholar
• Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–497.
   PubMed Web of Science ®Google Scholar
• Sabate E. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization; 2003.
   Google Scholar
• Cecilio SG, Pereira SADS, Pinto VDS, et al. Barriers experienced in self-care practice by young people with sickle cell disease hematological. Hematol Transfus Cell Ther. 2018;40(3):207–212.
   PubMedGoogle Scholar
• Rapoff M. Adherence to pediatric medical regimens. In: Issues in clinical child psychology. 2nd ed. New York (NY): Springer Science þ Business Media; 2010. p. 1–185.
   Google Scholar
• Haywood C, Jr., Beach MC, Bediako S, et al. Examining the characteristics and beliefs of hydroxyurea users and nonusers among adults with sickle cell disease. Am J Hematol. 2011;86(1):85–87.
   PubMed Web of Science ®Google Scholar
• Creary S, Zickmund S, Ross D, et al. Hydroxyurea therapy for children with sickle cell disease: describing how caregivers make this decision. BMC Res Notes. 2015;8:372.
   PubMedGoogle Scholar
• Connelly M, Wagner JL, Brown RT, et al. Informant discrepancy in perceptions of sickle cell disease severity. J Pediatr Psychol. 2005;30(5):443–448.
   PubMed Web of Science ®Google Scholar
• Badawy SM, Thompson AA, Liem RI. Beliefs about hydroxyurea in youth with sickle cell disease. Hematol Oncol Stem Cell Ther. 2018;11(3):142–148.
   PubMedGoogle Scholar
• Goodfellow NA, Hawwa AF, Reid AJ, et al. Adherence to treatment in children and adolescents with cystic fibrosis: a cross-sectional, multi-method study investigating the influence of beliefs about treatment and parental depressive symptoms. BMC Pulm Med. 2015;15:43.
   PubMed Web of Science ®Google Scholar
• Fosdal MB, Wojner-Alexandrov AW. Events of hospitalization among children with sickle cell disease. J Pediatr Nurs. 2007;22(4):342–346.
   PubMedGoogle Scholar
• Panepinto JA, Brousseau DC, Hillery CA, et al. Variation in hospitalizations and hospital length of stay in children with vaso-occlusive crises in sickle cell disease. Pediatr Blood Cancer. 2005;44(2):182–186.
   PubMed Web of Science ®Google Scholar
• Brousseau DC, Owens PL, Mosso AL, et al. Acute care utilization and rehospitalizations for sickle cell disease. JAMA. 2010;303(13):1288–1294.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2018. Mar 12 – Identifier NCT03462511, Hydroxyurea Adherence for Personal Best in Sickle Cell Disease (HABIT): Efficacy Trial; 2021 Feb 2 [cited 2021 Jan 17]. Available from: https://clinicaltrials.gov/ct2/show/NCT03462511.
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2019. Sep 6 – Identifier NCT04080167, Integration of mHEALTH Into the Care of Patients With Sickle Cell Disease to Increase Hydroxyurea Utilization; 2021 Dec 9 [cited 2021 Jan 17]; Available from: https://clinicaltrials.gov/ct2/show/NCT04080167.
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2020. Dec 30 – Identifier NCT04688411, An mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell Disease; 2021 Feb 17 [cited 2021 Jan 17]; Available from: https://clinicaltrials.gov/ct2/show/NCT04688411.
   Google Scholar